About Us
Our Story
Since its inception in 2019, BioLoomics has grown from a university laboratory into a cutting-edge facility. Our team of scientists, entrepreneurs, engineers, and business experts is driven to turn this breakthrough insight into next-generation complex antibodies for safer and more effective treatments which transform patients' lives.
.png)
Our Team
Doug Chapnick, PhD
Doug Chapnick, PhD
Dr. Doug Chapnick is a veteran of cell biology with 20 years’ experience engineering in the life sciences space. He led technology development and research in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder. He founded BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies. Doug received his PhD in Biochemistry from University of Colorado, Boulder, and has authored over 17 academic research publications ranging in focus from cell biology to drug mechanisms of action.
Jeremy Jacobsen, MS
Jeremy Jacobsen, MS
Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets. Prior to joining BioLoomics, he was an analyst for the DARPA Rapid Threat Assessment project at the University of Colorado, Boulder. He specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data.
MK Connacher, PhD
MK Connacher, PhD
MK has nearly ten years of experience in protein therapeutics. Before joining BioLoomics, she was at Mosaic Biosciences, where she led multiple partner programs. MK completed her PhD in the Pharmacology Department at the Johns Hopkins School of Medicine with a focus on enzymology and chemical biology. She has significant experience purifying difficult-to-express proteins from numerous expression systems and a strong analytical background to develop assays for protein characterization, cellular signaling, and PK/PD measurements from animal samples
Mike Minson, PhD
Mike Minson, PhD
Mike is an experienced research biochemist coming from ArcherDX and Sartorius with expertise in developing high throughput assays for cell screening using a variety of techniques including NGS, microscopy, and flow cytometry. During his postdoctoral and graduate work at the University of Colorado Boulder, he studied the immune response to bacterial infection using FRET biosensors in primary macrophages. Mike is focused on bringing the drug discovery and downstream analysis of candidates to scale.
Clara Ross, MS
Clara Ross, MS
Clara is a protein scientist coming from Watchmaker Genomics with 4+ years of experience in protein purification ranging from small scale prototyping to large scale manufacturing. She has additional experience in protein expression, characterization and DNA/RNA library preparation. Prior to her work in industry, Clara obtained her master’s degree from New Mexico State University where she studied Rho Family GTPases during oocyte meiosis using fluorescent biosensors and 3D live-cell microscopy.
Claire Armstrong, PhD
Claire Armstrong, PhD
Claire has over 10 years of experience as a research scientist, specializing in high-throughput assay development, cellular signaling, and single-cell fluorescence microscopy. During her PhD and postdoctoral work at the University of Colorado, she studied the molecular mechanisms driving cell-cycle commitment using single-cell timelapse microscopy of fluorescent biosensors. Claire specializes in driving forward the selection and validation of therapeutic antibody scaffolds via cell-based assay development, single-cell screening, and cell picking microscopy.
Rachel Langston, PhD
Rachel Langston, PhD
Rachel is an experienced molecular biologist coming from Inscripta with expertise in DNA repair and genetics. She is skilled at developing protocols for large-scale mutagenesis. During her postdoctoral work at the IBPC she developed a novel CRISPR-based protocol to study DNA replication and telomere regulation. At BioLoomics, Rachel is focused on optimizing and scaling library production to more efficiently identify drug candidates.
Humza Ashraf, PhD
Humza Ashraf, PhD
Humza is a Systems Biologist with knowledge and expertise in cell biology, computational biology, quantitative and high throughput, fluorescence microscopy, live-cell imaging, flow cytometry, single-cell analysis, and cancer biology. During his graduate work at the University of Colorado Boulder, he studied single-cell fate variability in the proliferative responses of cancer cells to acute chemotherapy treatment. Humza is passionate about leveraging novel tools and methods to extract meaningful insights into complex biological processes.
Nicole Beach
Nicole Beach
Nicole has over 20 years of experience as an Office Manager and Human Resources professional with experience in event planning, team building, and employee workplace management and deep experience in startups. With a Masters degree in Organizational Leadership specializing in HR Management, she is highly organized, extremely personable and professional.
Kaitlyn Shafer
Kaitlyn Shafer
Kaitlyn holds a BS in Biochemistry from the University of Denver. She has experience implementing and creating quality control standards and protocols in the diagnostic industry. At BioLoomics, she supports our DNA and cell biology scientists with a wide range of daily tasks including solution preparation, experimental support at different stages, and inventory management. She's focused on developing industry skills in preparation for pursuing a graduate degree.
Ted Kee
Ted Kee
Ted has over 12 years of biotech industry experience, specializing in Manufacturing Science and Technology (MSAT). He has held process development and engineering positions at several industry-leading pharmaceutical companies. Ted relocated to Colorado from California in 2019 to co-found BioLoomics and lead the effort to streamline, standardize, and scale up BioLoomics’ laboratory operations.
Doug Chapnick, PhD
Doug Chapnick, PhD
Dr. Doug Chapnick is a veteran of cell biology with 20 years’ experience engineering in the life sciences space. He led technology development and research in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder. He founded BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies. Doug received his PhD in Biochemistry from University of Colorado, Boulder, and has authored over 17 academic research publications ranging in focus from cell biology to drug mechanisms of action.
Jeremy Jacobsen, MS
Jeremy Jacobsen, MS
Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets. Prior to joining BioLoomics, he was an analyst for the DARPA Rapid Threat Assessment project at the University of Colorado, Boulder. He specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data.
MK Connacher, PhD
MK Connacher, PhD
MK has nearly ten years of experience in protein therapeutics. Before joining BioLoomics, she was at Mosaic Biosciences, where she led multiple partner programs. MK completed her PhD in the Pharmacology Department at the Johns Hopkins School of Medicine with a focus on enzymology and chemical biology. She has significant experience purifying difficult-to-express proteins from numerous expression systems and a strong analytical background to develop assays for protein characterization, cellular signaling, and PK/PD measurements from animal samples
Mike Minson, PhD
Mike Minson, PhD
Mike is an experienced research biochemist coming from ArcherDX and Sartorius with expertise in developing high throughput assays for cell screening using a variety of techniques including NGS, microscopy, and flow cytometry. During his postdoctoral and graduate work at the University of Colorado Boulder, he studied the immune response to bacterial infection using FRET biosensors in primary macrophages. Mike is focused on bringing the drug discovery and downstream analysis of candidates to scale.
Clara Ross, MS
Clara Ross, MS
Clara is a protein scientist coming from Watchmaker Genomics with 4+ years of experience in protein purification ranging from small scale prototyping to large scale manufacturing. She has additional experience in protein expression, characterization and DNA/RNA library preparation. Prior to her work in industry, Clara obtained her master’s degree from New Mexico State University where she studied Rho Family GTPases during oocyte meiosis using fluorescent biosensors and 3D live-cell microscopy.
Claire Armstrong, PhD
Claire Armstrong, PhD
Claire has over 10 years of experience as a research scientist, specializing in high-throughput assay development, cellular signaling, and single-cell fluorescence microscopy. During her PhD and postdoctoral work at the University of Colorado, she studied the molecular mechanisms driving cell-cycle commitment using single-cell timelapse microscopy of fluorescent biosensors. Claire specializes in driving forward the selection and validation of therapeutic antibody scaffolds via cell-based assay development, single-cell screening, and cell picking microscopy.
Rachel Langston, PhD
Rachel Langston, PhD
Rachel is an experienced molecular biologist coming from Inscripta with expertise in DNA repair and genetics. She is skilled at developing protocols for large-scale mutagenesis. During her postdoctoral work at the IBPC she developed a novel CRISPR-based protocol to study DNA replication and telomere regulation. At BioLoomics, Rachel is focused on optimizing and scaling library production to more efficiently identify drug candidates.
Humza Ashraf, PhD
Humza Ashraf, PhD
Humza is a Systems Biologist with knowledge and expertise in cell biology, computational biology, quantitative and high throughput, fluorescence microscopy, live-cell imaging, flow cytometry, single-cell analysis, and cancer biology. During his graduate work at the University of Colorado Boulder, he studied single-cell fate variability in the proliferative responses of cancer cells to acute chemotherapy treatment. Humza is passionate about leveraging novel tools and methods to extract meaningful insights into complex biological processes.
Nicole Beach
Nicole Beach
Nicole has over 20 years of experience as an Office Manager and Human Resources professional with experience in event planning, team building, and employee workplace management and deep experience in startups. With a Masters degree in Organizational Leadership specializing in HR Management, she is highly organized, extremely personable and professional.
Kaitlyn Shafer
Kaitlyn Shafer
Kaitlyn holds a BS in Biochemistry from the University of Denver. She has experience implementing and creating quality control standards and protocols in the diagnostic industry. At BioLoomics, she supports our DNA and cell biology scientists with a wide range of daily tasks including solution preparation, experimental support at different stages, and inventory management. She's focused on developing industry skills in preparation for pursuing a graduate degree.
Ted Kee
Ted Kee
Ted has over 12 years of biotech industry experience, specializing in Manufacturing Science and Technology (MSAT). He has held process development and engineering positions at several industry-leading pharmaceutical companies. Ted relocated to Colorado from California in 2019 to co-found BioLoomics and lead the effort to streamline, standardize, and scale up BioLoomics’ laboratory operations.
Our Board Members and Advisors
Nicholas Saccomano, PhD
Nicholas Saccomano, PhD
Nick Saccomano joins the BioLoomics board of directors with over 35 years of research, development, and management experience across a multitude of therapeutic areas. Nick most recently served as Chief Science Officer and site head at Pfizer Boulder R & D, formally Array BioPharma Inc., where he grew and advanced a portfolio of small molecule oncology programs from inception to proof-of-concept. Over his varied career, Dr. Saccomano has guided the discovery and development of dozens of molecules resulting in several commercial introductions. Nick’s appointment will complement the strengths of the BioLoomics leadership and advisory groups, while contributing deep insights into platform development, strategic direction and portfolio/clinical applications.
Joel Dudley, PhD
Joel Dudley, PhD
Joel is a partner at Innovation Endeavors and an experienced leader, medical professional, researcher, and entrepreneur. Joel previously served as the Chief Scientific Officer at Tempus, a company focused on bringing the power of data and artificial intelligence to healthcare. Before joining Tempus, Joel was an Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. He also served as Executive Vice President for Precision Health for the Mount Sinai Health System. Prior to joining Innovation Endeavors, Joel co-founded Onegevity Health (acquired by Thorne), a company developing health intelligence platforms for preventative health, and NuMedii, a company developing machine learning and A.I. approaches for drug discovery. Joel earned a BS in Microbiology from Arizona State University and an MS and Ph.D. in Biomedical Informatics from the Stanford University School of Medicine.
Natanel Barookhian
Natanel Barookhian
Starting with $10K in personal funds, Natanel Barookhian has guided, pruned, and grown TechU into one of the most selective and best-performing seed funds on the East Coast. Born into a single-parent home of modest means, Natanel’s worldview was shaped by early immigration to the United States. Armed with four languages and an MBA from MIT, he engages tenacious entrepreneurs from around the world in search of next-generation deep tech with lasting implications.
Jeanne Stachowiak, PhD
Jeanne Stachowiak, PhD
Professor Stachowiak is a Professor at UT Austin, Texas. Her interests are the biophysical mechanisms that underlie the function of lipid membranes in cells and creation of bio-inspired materials and systems that borrow these mechanisms. Themes of her work include: understanding how proteins and lipid domains modify the fluidity, reactivity, and 3D architecture of membranes, examining how confinement within a lipid vesicle influences biochemical reactions and spatial organization of biochemical components and using the organizational principles of the lipid membrane to build functional systems such as assays, drug carriers, and environmentally responsive materials.
Chris Bahl, PhD
Chris Bahl, PhD
Dr. Bahl is the President, CSO and Co-founder of AI Proteins in Boston, is an established leader in the protein design field, and was a 2019 TED Fellow. He holds a Ph.D. in Biochemistry from Geisel School of Medicine at Dartmouth, an MS in Biochemistry, and BS in Biochemistry, Molecular & Cellular Biology from the University of Maine. He pioneered the ability to computationally design miniproteins de novo as a postdoctoral fellow with Dr. David Baker at the University of Washington’s Institute for Protein Design in Seattle. Following his Post-Doc, he joined the Institute for Protein Innovation in Boston as one of the founding faculty members, with co-appointments at Boston Children’s Hospital and Harvard Medical School.
Michael Stowell, PhD
Michael Stowell, PhD
Michael Stowell is CSO of AmideBio and an Associate Professor of Molecular Biology and Mechanical Engineering at the University of Colorado, Boulder. He has authored numerous publications in the fields of synthetic organic chemistry, structural biology, neurobiology, and biophysics. Michael has received multiple grants and awards including the Beckman Young Investigator Award, a National Institutes of Health EUREKA award and a Howard Hughes Medical Institute Collaborative Innovation Award. Michael received his Ph.D. in Chemistry and Biophysics from the California Institute of Technology and was a visiting Scientist at the MRC – Laboratory of Molecular Biology, Cambridge England and the Biophysics Department of Kyoto University, Japan.
Viswa Colluru, PhD
Viswa Colluru, PhD
Viswa is the founder and CEO of Enveda Biosciences. He has led the company through successful fundraising rounds and the scale-up of its discovery platform, which is based on metabolomics and machine learning, to unearth new medicines from its first-of-a-kind chemical map of the natural world. Before founding Enveda, Viswa led multiple drug development efforts at Recursion Pharmaceuticals. He earned his Ph.D. in immuno-oncology at the University of Wisconsin-Madison, where he developed candidate therapeutics for prostate cancer. Outside of work, Viswa loves playing racquet sports of all kinds and trying to read about a dozen books in parallel.
William Kohlbrenner, PhD
William Kohlbrenner, PhD
Bill is a pharma and biotech veteran with extensive research and business development experience. He spent most of his career at AbbVie where he directed drug discovery programs in oncology, antivirals and antibacterials. He later led a global technology scouting team as part of the business development organization. Prior to joining BioLoomics in 2021 Bill was CEO of a start-up focused on Alzheimer’s disease and CSO of a Boston-based company offering fund-raising services to early-stage entrepreneurs.
Our Investors
Who We Are
